Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plasma and intrapulmonary pharmacokinetics of piperacillin/tazobactam in critically ill patients
2011-004470-28Phase 4Completed
- Sponsor
- Manchester University NHS Foundation Trust
- Start
- Sep 2011
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of piperacillin + tazobactam in ventilator-associated pneumonia (VAP) and critical illness, sponsored by Manchester University NHS Foundation Trust. Primary endpoints: Blood concentrations of piperacillin, Blood concentrations of tazobactam and 3 more. Started Sep 2011; status: completed.
02
Drugs
piperacillin + tazobactam
03
Conditions
ventilator-associated pneumonia (VAP)critical illness
Beyond the preview
Go deeper on 2011-004470-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004470-28.